Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Aaron Spector

Nurse Practitioner, Psychiatric/Mental Health Marlton, NJ Nurse Practitioner

NPI 1619077716 CMS profile 10448063

765 Route 70 E Bldg A100, Marlton, NJ 08053

Open in the dashboard

General payments

$100,357

648 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Aaron Spector of Marlton, NJ is reported in the CMS Open Payments database as having received $100,357 across 648 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $15,887 78
2024 General $20,933 109
2023 General $24,376 118
2022 General $20,510 163
2021 General $18,651 180

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Aaron Spector
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Aaron Spector were reported at $15,887. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year Aaron Spector Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $18,651 $166 $54–$482 $132
2022 $20,510 $195 $66–$559 $149
2023 $24,376 $233 $82–$673 $160
2024 $20,933 $236 $84–$688 $164
2025 $15,887 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Otsuka America Pharmaceutical, Inc. $53,779 200 payments
  2. AbbVie, Inc. $33,144 152 payments
  3. E.R. Squibb & Sons, L.L.C. $5,696 21 payments
  4. Alkermes, Inc. $3,658 32 payments
  5. Sunovion Pharmaceuticals Inc. $707 39 payments
  6. Bausch Health US, LLC $670 46 payments
  7. Teva Pharmaceuticals USA, Inc. $536 7 payments
  8. ITI, Inc. $437 33 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $316 24 payments
  10. Axsome Therapeutics, Inc. $237 15 payments
  11. Other $1,178 79 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $83,985 100 payments
  2. Food and Beverage $9,137 479 payments
  3. Consulting Fee $4,238 5 payments
  4. Travel and Lodging $2,989 62 payments
  5. Education $7 2 payments
Products named General payments · program years 2021–2025
  1. REXULTI $32,483 126 payments
  2. VRAYLAR Neuroscience $27,469 145 payments
  3. ABILIFY MAINTENA $21,384 80 payments
  4. ABILIFY ASIMTUFII $11,433 42 payments
  5. VRAYLAR Neuroscience $5,675 7 payments
  6. ARISTADA Cns $3,196 26 payments
  7. ARISTADA Cns $3,196 26 payments
  8. ARISTADA INITIO $3,163 24 payments
  9. ARISTADA Cns $3,088 11 payments
  10. ARISTADA Cns $3,088 11 payments
  11. Other $6,424 316 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 54 drugs

Part D claims

2,013

Median for Certified Clinical Nurse Specialist: 344

Drug cost

$222,661

Median for Certified Clinical Nurse Specialist: $20,739

Branded share of claims

22.3%

Median for Certified Clinical Nurse Specialist: 20.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Fanapt Iloperidone Brand 17 $54,040
Rexulti Brexpiprazole Brand 36 $52,116
Vraylar Cariprazine Hcl Brand 18 $31,300
Trintellix Vortioxetine Hydrobromide Brand 25 $16,047
Vyvanse Lisdexamfetamine Dimesylate Brand 13 $5,437
Vilazodone Hcl Generic 40 $5,239
Paliperidone Er Paliperidone Brand 22 $5,084
Clozapine Generic 11 $4,318
Duloxetine Hcl Generic 132 $4,061
Lisdexamfetamine Dimesylate Generic 13 $3,614

The 10 drugs with the highest cost, of 54 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,644 Part D prescribers listed as Certified Clinical Nurse Specialist; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 3 billing codes

Paid by Medicare

$32,894

Medicare's payments for the services billed

Medicare patients

57

Average age 60

Services billed

526

35 women, 22 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 68%
High blood pressure 54%
Arthritis 30%
Diabetes 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Otsuka America Pharmaceutical, Inc. $7,110
  • Lundbeck LLC $15
$7,125 36 —
VRAYLAR
  • AbbVie, Inc. $3,066
$3,066 18 —
ABILIFY ASIMTUFII
  • Otsuka America Pharmaceutical, Inc. $2,587
$2,587 — —
ABILIFY MAINTENA
  • Otsuka America Pharmaceutical, Inc. $2,587
$2,587 — —
APLENZIN
  • Bausch Health US, LLC $113
$113 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

648 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Psychiatric/Mental Health in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record